The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide ...

A new class-action lawsuit alleges CVS Caremark unlawfully changed its coverage for popular GLP-1 drug Zepbound. | A new ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...

A class action lawsuit has been filed against CVS Caremark (NYSE:CVS), the pharmacy benefit manager for health insurer Aetna, ...

Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the ...

A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

CVS Caremark was sued Wednesday by two health plan participants who say the pharmacy benefit manager wrongly refuses to cover ...

Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a ...

Cigna (CI) reports flat employer coverage rates for obesity drugs like Wegovy from Novo Nordisk (NVO) and Zepbound from Eli ...

Benefits consultants Aon and WTW told the Wall Street Journal that employer health-coverage costs are set to surge about 9.5% ...